ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Clinical Trials Study |
Article Title |
Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Xiao-Yan Jiang, Bing Huang, Dan-Ping Huang, Chun-Shan Wei, Wei-Chao Zhong, De-Ti Peng, Fu-Rong Huang and Guang-Dong Tong |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Natural Science Foundation of China |
81174263 |
Sanming Project of Medicine in Shenzhen, Guangdong Province, China |
SZSM201612074 |
Shenzhen Science and Technology Project, Guangdong Province, China |
201202154 |
|
Corresponding Author |
Guang-Dong Tong, MD, PhD, Chief Physician, Professor, Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, No. 1 Fuhua Road, Shenzhen 518033, Guangdong Province, China. tgd755@163.com |
Key Words |
Chronic hepatitis B; Anti-inflammatory therapy; Hepatoprotective therapy; Cumulative incidence; Hepatocellular carcinoma; Antiviral therapy |
Core Tip |
According to the status quo of antiviral therapy for chronic hepatitis B (CHB) in China, we conducted long-term follow-up of patients with CHB who were recommended to receive nucleoside antiviral therapy in accordance with the guidelines, but did not receive antiviral therapy. We found that early antiviral therapy in patients with CHB did not yield greater benefits in the incidence of hepatocellular carcinoma than hepatoprotective anti-inflammatory therapy. It is suggested that early antiviral therapy with nucleosides may mask spontaneous viral clearance and hepatitis B e antigen clearance in patients with CHB. |
Publish Date |
2021-03-17 06:19 |
Citation |
Jiang XY, Huang B, Huang DP, Wei CS, Zhong WC, Peng DT, Huang FR, Tong GD. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol 2021; 27(11): 1101-1116 |
URL |
https://www.wjgnet.com/1007-9327/full/v27/i11/1101.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v27.i11.1101 |